ifinatamab deruxtecan
Sponsor MRK · listed as MRK
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
ifinatamab deruxtecan is a clinical-stage drug asset sponsored by MRK, listed as MRK. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Apr 30, 2027 (day precision, medium confidence), tied to trial NCT06203210. The asset is in Phase 3 and currently recruiting, studied in Small Cell Lung Cancer. It appears across 3 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2027-04-30
As disclosedApr 30, 2027
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06203210
PhasePHASE3
StatusRECRUITING
Lead sponsorDaiichi Sankyo
Listed asMRK
Condition(s)Small Cell Lung Cancer
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More MRK catalysts